COVID-19 vaccination and antirheumatic therapy

被引：83

作者：

Arnold, Jack ^{[1
]}

Winthrop, Kevin ^{[2
]}

Emery, Paul ^{[1
,3
]}

机构：

[1] Univ Leeds, Chapel Allerton Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Chapeltown Rd, Leeds LS7 4SA, W Yorkshire, England

[2] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA

[3] Leeds Teaching Hosp NHS Trust, NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England

来源：

RHEUMATOLOGY | 2021年 / 60卷 / 08期

关键词：

COVID-19; vaccine; biologics; DMARDs; rituximab; methotrexate; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; RHEUMATOID-ARTHRITIS; INFLUENZA VACCINE; IMMUNE-RESPONSE; ANTIBODY-RESPONSES; A/H1N1; VACCINATION; TNF BLOCKERS; METHOTREXATE; TOFACITINIB; RITUXIMAB;

D O I：

10.1093/rheumatology/keab223

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The coronavirus disease 2019 (COVID-19) vaccination will be the largest vaccination programme in the history of the NHS. Patients on immunosuppressive therapy will be among the earliest to be vaccinated. Some evidence indicates immunosuppressive therapy inhibits humoral response to the influenza, pneumococcal and hepatitis B vaccines. The degree to which this will translate to impaired COVID-19 vaccine responses is unclear. Other evidence suggests withholding MTX for 2 weeks post-vaccination may improve responses. Rituximab has been shown to impair humoral responses for 6 months or longer post-administration. Decisions on withholding or interrupting immunosuppressive therapy around COVID-19 vaccination will need to be made prior to the availability of data on specific COVID-19 vaccine response in these patients. With this in mind, this article outlines the existing data on the effect of antirheumatic therapy on vaccine responses in patients with inflammatory arthritis and formulates a possible pragmatic management strategy for COVID-19 vaccination.

引用

收藏

页码：3496 / 3502

页数：7

相关论文

共 38 条

[21] Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: A controlled trial [J].

Keshtkar-Jahromi, Maryam ;

Argani, Hassan ;

Rahnavardi, Mohammad ;

Mirchi, Elham ;

Atabak, Shahnaz ;

Tara, Seied Ahmad ;

Gachkar, Latif ;

Noori-Froothghe, Azam ;

Mokhtari-Azad, Talat .

AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (04) :654-660

[22] Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial [J].

Kivitz, Alan J. ;

Schechtman, Joy ;

Texter, Michele ;

Fichtner, Andreas ;

de Longueville, Marc ;

Chartash, Elliot K. .

JOURNAL OF RHEUMATOLOGY, 2014, 41 (04) :648-657

[23] SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls [J].

Le Bert, Nina ;

Tan, Anthony T. ;

Kunasegaran, Kamini ;

Tham, Christine Y. L. ;

Hafezi, Morteza ;

Chia, Adeline ;

Chng, Melissa Hui Yen ;

Lin, Meiyin ;

Tan, Nicole ;

Linster, Martin ;

Chia, Wan Ni ;

Chen, Mark I-Cheng ;

Wang, Lin-Fa ;

Ooi, Eng Eong ;

Kalimuddin, Shirin ;

Tambyah, Paul Anantharajah ;

Low, Jenny Guek-Hong ;

Tan, Yee-Joo ;

Bertoletti, Antonio .

NATURE, 2020, 584 (7821) :457-+

[24] Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis [J].

Mori, Shunsuke ;

Ueki, Yukitaka ;

Hirakata, Naoyuki ;

Oribe, Motohiro ;

Hidaka, Toshihiko ;

Oishi, Kazunori .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (12) :2006-2010

[25] Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases [J].

Nuno, Laura ;

Navarro, Marta Novella ;

Bonilla, Gema ;

Franco-Gomez, Karen ;

Aguado, Pilar ;

Peiteado, Diana ;

Monjo, Irene ;

Tornero, Carolina ;

Villalba, Alejandro ;

Miranda-Carus, Maria-Eugenia ;

De Miguel, Eugenio ;

Bogas, Patricia ;

Castilla-Plaza, Ana ;

Bernad-Pineda, Miguel ;

Garcia-Lorenzo, Elena ;

Rodriguez-Araya, Tamara ;

Balsa, Alejandro .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (12) :1659-+

[26] Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response [J].

Oren, S. ;

Mandelboim, M. ;

Braun-Moscovici, Y. ;

Paran, D. ;

Ablin, J. ;

Litinsky, I. ;

Comaneshter, D. ;

Levartovsky, D. ;

Mendelson, E. ;

Azar, R. ;

Wigler, I. ;

Balbir-Gurman, A. ;

Caspi, D. ;

Elkayam, O. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) :937-941

[27] Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial [J].

Park, Jin Kyun ;

Choi, Yunhee ;

Winthrop, Kevin L. ;

Song, Yeong Wook ;

Lee, Eun Bong .

ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (09) :1283-1284

[28] Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial [J].

Park, Jin Kyun ;

Lee, Yun Jong ;

Shin, Kichul ;

Ha, You-Jung ;

Lee, Eun Young ;

Song, Yeong Wook ;

Choi, Yunhee ;

Winthrop, Kevin L. ;

Lee, Eun Bong .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (06) :898-904

[29]

Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7

[30] Abatacept and Reduced Immune Response to Pandemic 2009 Influenza A/H1N1 Vaccination in Patients With Rheumatoid Arthritis [J].

Ribeiro, Ana C. ;

Laurindo, Ieda M. ;

Guedes, Lissiane K. ;

Saad, Carla G. ;

Moraes, Julio C. ;

Silva, Clovis A. ;

Bonfa, Eloisa .

ARTHRITIS CARE & RESEARCH, 2013, 65 (03) :476-480

← 1 2 3 4 →